Recent results from large phase II/III clinical trials on adenoviral-mediated VEGF delivery have been inconclusive if not disappointing so far. We believe a sounder strategy may be to take advantage of the HIF-1? upstream transcriptional regulator that can activate several downstream genes such as VEGF, FGF, IGF, angiopoietin, and erythropoietin. However, HIF-1? has a short biological half-life due to endogenous degradation by prolyl hydroxylase-2 (PHD2). Therefore, we hypothesize that short hairpin inhibition of PHD2 (shPHD2) represent a novel approach to induce therapeutic angiogensis. On the flip side, persistent and unregulated angiogenesis can lead to hemangioma in the heart and thus controlling gene expression in a targeted and regulatory fashion is needed. Another priority is to develop novel techniques that can be used to track gene expression in living subjects noninivasively, longitudinally, and quantitatively. Thus, the primary goal of this R01 proposal is to use our multi-disciplinary expertise in vector design, molecular imaging, vascular biology, and translational models to address the above questions.
Our specific aims are to (1) develop smart vectors with robust and prolonged transgene expression, (2) monitor the pharmacokinetics and biodistribution of our novel vector in vivo, (3) demonstrate mechanisms of shPHD2 mediated gene therapy for myocardial ischemia, and (4) evaluate the safety, efficacy, and optimal delivery conditions in translational models. At the end of 5 years, we hope to translate these findings to treatment of coronary artery disease patients with our novel smart vector systems.

Public Health Relevance

Although initial phase 1 trials in patients with myocardial ischemia provided encouraging results, recent phase 2 randomized trials (AGENT, VIVA, KAT) yielded only modest benefits. These inconsistencies have been attributed to lack of ideal delivery vectors, unclear role of single therapeutic gene such as VEGF, suboptimal dosing or route of administration, and inability to monitor gene transfer in patients. For the field to move forward, the pressing questions that need to be resolved are: (i) finding a suitable vector to overcome physical barriers, (ii) develop a novel method mean to verify gene expression in vivo, (iii) dissect the molecular mechanisms of gene therapy, and (iv) demonstrate safety and efficacy in translational models. The significance of this R01 proposal is to validate that chemical conjugation can be used to significantly improve the transfection efficiency of plasmid DNA, that novel molecular imaging platforms will allow us to monitor the pharmacokinetics and biodistribution of gene therapy in living subjects, that a smart vector system can be designed to be tissue specific and hypoxia responsive, and finally that gene therapy can be used in small animals, large animals, and human subjects in the future.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL093172-06
Application #
8653002
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Danthi, Narasimhan
Project Start
2009-04-15
Project End
2015-11-30
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$392,000
Indirect Cost
$147,000
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pavo, Noemi; Emmert, Maximilian Y; Giricz, Zoltán et al. (2014) On-line visualization of ischemic burden during repetitive ischemia/reperfusion. JACC Cardiovasc Imaging 7:956-8
Kooreman, Nigel G; Ransohoff, Julia D; Wu, Joseph C (2014) Tracking gene and cell fate for therapeutic gain. Nat Mater 13:106-9
Nguyen, Patricia K; Riegler, Johannes; Wu, Joseph C (2014) Stem cell imaging: from bench to bedside. Cell Stem Cell 14:431-44
Chen, Heidi I; Poduri, Aruna; Numi, Harri et al. (2014) VEGF-C and aortic cardiomyocytes guide coronary artery stem development. J Clin Invest 124:4899-914
Cheng, Kai; Kothapalli, Sri-Rajasekhar; Liu, Hongguang et al. (2014) Construction and validation of nano gold tripods for molecular imaging of living subjects. J Am Chem Soc 136:3560-71
Lijkwan, Maarten A; Hellingman, Alwine A; Bos, Ernst J et al. (2014) Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia. Hum Gene Ther 25:41-9
Ong, Sang-Ging; Lee, Won Hee; Huang, Mei et al. (2014) Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer. Circulation 130:S60-9
Keeney, Michael; Ong, Sang-Ging; Padilla, Amanda et al. (2013) Development of poly(*-amino ester)-based biodegradable nanoparticles for nonviral delivery of minicircle DNA. ACS Nano 7:7241-50
Chen, Ian Y; Gheysens, Olivier; Li, Zongjin et al. (2013) Noninvasive imaging of hypoxia-inducible factor-1* gene therapy for myocardial ischemia. Hum Gene Ther Methods 24:279-88
Hu, Shijun; Wilson, Kitchener D; Ghosh, Zhumur et al. (2013) MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells 31:259-68

Showing the most recent 10 out of 27 publications